NICK PAPPAS JOINS PAPPAS CAPITAL AS MANAGING PARTNER
Strengthens Team in Support of Firm's Continued Growth and Expansion
"Nick's extensive investment experience, coupled with his proven leadership skills, make him the ideal executive to help manage our venture business," said
Nick added, "Over the past 29 years, Pappas Capital has developed a reputation for partnering with entrepreneurs to build innovative companies that advance healthcare technologies and bring groundbreaking solutions to market. I am thrilled to have the opportunity to work with the Pappas team and look forward to building on their strong track-record of developing innovative products to address significant unmet medical needs."
Nick has over two decades of investing, banking and management experience with early-stage healthcare and technology companies. Prior to Philips, he spent seven years as a Partner and venture investor with MassVentures. Previously, Nick was a senior technology investment banker with Oppenheimer & Co., SVB Alliant, and Canaccord Genuity, both in
About Pappas Capital
Pappas Capital is a global venture capital and commercial development firm investing in next-generation life science, agriculture, and technology companies. The firm has raised more than
Investor and Media Contact:
919-998-3308
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/nick-pappas-joins-pappas-capital-as-managing-partner-301931205.html
SOURCE Pappas Capital
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CANADIAN SPACE AGENCY AND MDA SPACE CONCLUDE CONTRACT FOR REPLENISHMENT SATELLITE VALUED AT $688M
- Farm Rich Brings Soccer Watch Parties to Life with a Custom Foosball Table Giveaway
- A New Era of School Storytelling Begins: DistrictWON Announces a $20+ Million Historic Investment in School News
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Canaccord Genuity, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share